IBM Beats Peers on Price, but Q3 Print Arrives Tonight

IBM rose 4.8% over the past week to $241.92, a sharper move than the median of its closest correlated peers, which gained roughly 0.9% across the same period. That outperformance is notable against a mixed backdrop: KD climbed 13.5% and DXC 14.6%, but BBAI dropped 9.2% and UIS was essentially flat. IBM's gain sits in the middle of a wide peer dispersion rather than at the top, but the stock is meaningfully less shorted than most of those names, which kept it out of the cross-fire during any momentum-driven selling earlier in the month.

The positioning picture into tonight's Q3 release is calm by almost every measure. Short interest edged down fractionally on the day to 23.5 million shares, or 2.5% of the free float, and has pulled back slightly from the 23.6 million shares recorded on October 12. The one-month build of roughly 10% is real, but the absolute level remains low, and the lending market is nowhere near tight: availability is at 8,179% of short interest, meaning there are dozens of lendable shares for every one already borrowed, up from around 5,300% a month ago as the pool of available stock has expanded even as shorts added. The cost to borrow, at 0.40%, has eased over the week and over the month. Morgan Stanley's Erik Woodring raised his price target to $238 from $190 on October 15, keeping an Equal-Weight rating, which is worth noting because the prior target looked stale against a stock that had already recovered to the low $230s. RBC maintained its $270 Outperform, and Truist initiated at Hold with a $240 target on October 9. The mean analyst target of $243 is now barely above the current price, which leaves the Street roughly in line with the tape rather than pointing meaningfully higher or lower.

The fundamental debate has two clean sides. The bull case rests on a revenue base that is roughly 50% recurring and roughly 75% software, with Red Hat expected to grow in double digits and IBM's AI and hybrid cloud positioning giving it access to 95% of Fortune 500 clients through existing relationships. Annual recurring revenue growth has accelerated to 8% year on year, and free cash flow durability is a key part of the investment thesis, with management guiding for at least $1 billion of FCF expansion at the low end of guidance. The bear case starts with July's guidance cut, which brought full-year revenue growth down to 4 to 5% in constant currency, and continues with competitive pressure in consulting and an estimated 10 to 12% year-on-year decline in mainframe software revenue in the most recent quarter. The PE stands at 18.6 times, up roughly 0.7 points over the past month as the stock recovered, and the EV/EBITDA is at 13.2 times. On factor scores, the dividend rank of 99 is the standout. EPS momentum scores are soft, at 27 on the 30-day measure and 38 on 90 days, and the forward EPS growth score of 12 reflects lingering concern about the earnings trajectory beyond this print.

IBM's two most recent earnings releases generated the same one-day reaction: a decline of roughly 1.8% on July 22 after Q2 results. The five-day move after that print was a recovery of 7.6%, and the Q1 print in late April produced a smaller decline of 0.4% on the day followed by a muted five-day move of 0.4%. The pattern is consistent: modest day-one weakness followed by a recovery as the market digests the numbers. Options are not pricing in unusual fear. The put/call ratio of 0.83 is almost exactly at its 20-day average of 0.83, with a z-score near zero, and the ratio is well inside its 52-week range of 0.64 to 1.05. There is no sign of elevated hedging demand going into the release.

The number that changes the picture tonight is guidance. Revenue growth in constant currency for full-year 2026, whether it comes in at the low end, the mid-point, or above the 4 to 5% range management set in July, is the variable the Street is pricing around at a $242 stock with a $243 mean target and an earnings print due after the close.